GRAL
GRAIL, LLCNASDAQHEALTHCAREDIAGNOSTICS & RESEARCH
Key Statistics
Market Cap
$2.88B
P/E Ratio
—
EPS
$-10.30
Beta
—
52W High
$118.84
52W Low
$29.95
50-Day MA
$53.66
200-Day MA
$68.72
Dividend Yield
—
Profit Margin
-253.20%
Forward P/E
—
PEG Ratio
—
About GRAIL, LLC
GRAIL, LLC is a pioneering biotechnology company at the forefront of cancer diagnostics, focusing on innovative blood tests for multi-cancer early detection (MCED) that utilize its proprietary genomic technologies. Committed to advancing precision medicine, GRAIL aims to transform the oncology landscape by providing individuals with essential insights for proactive health management and improving overall patient outcomes. Its groundbreaking efforts address significant unmet needs in cancer screening and diagnostics, positioning the company as a key player in the rapidly evolving field of cancer care.
Fundamentals
| Revenue (TTM) | $156.12M |
| Gross Profit (TTM) | $76.94M |
| EBITDA | $-360.50M |
| Operating Margin | -332.90% |
| Return on Equity | -16.10% |
| Return on Assets | -11.40% |
| Revenue/Share (TTM) | $4.07 |
| Book Value | $60.79 |
| Price-to-Book | 1.15 |
| Price-to-Sales (TTM) | 18.47 |
| EV/Revenue | 13.52 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 28.10% |
| Shares Outstanding | $42.92M |
| Float | $33.69M |
| % Insiders | 4.72% |
| % Institutions | 83.58% |
Historical Volatility
HV 10-Day
50.89%
HV 20-Day
76.23%
HV 30-Day
69.72%
HV 60-Day
72.45%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($66.86 target)
4
Buy4
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026